Ultragenyx Pharmaceutical Inc. (RARE)

NMS – Цена в реальном времени. Валюта: USD

30.77

+1.52 (5.20%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

30.77

0.00 (0.00%)

После закрытия: Jun 26, 2026, 6:54 PM EDT

09.06.2026

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

04.06.2026

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab's potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.

04.06.2026

Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

03.06.2026

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET.

01.06.2026

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab's potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.

22.05.2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company's common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

13.05.2026

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
RARE	Wells Fargo	Overweight	undefined >> $65	October 20th 2025
RARE	H.C. Wainwright	Buy	undefined >> $80	July 28th 2025

Пресс-релизы

04.06.2026

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

01.06.2026

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

22.05.2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06.05.2026

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and Joshua Higa, Chief of Staff and Vice President of investor relations, will participate in a fireside at Bank of America's 2026 Healthcare Conference on Tuesday, May 12, 2026, at 2:20 PM PT.

Ultragenyx Pharmaceutical Inc. (RARE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Search stocks

Ultragenyx Pharmaceutical Inc. (RARE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference